This protocol is judged by an institutional overview board, an impartial group that evaluations any medical trials involving human beings. If a review will involve a Schedule I drug, as soon as the board approves the protocol as ethical, the researchers have to apply for an investigational new drug (IND) number within the FDA.Using the doses packag